Vision Preservation in Eyes of Polypoidal Choroidal Vasculopathy with Low-Dose Intravitreal Triamcinolone Acetonide
| Autor: | Hsiang-Wen Chien, Yi-Ru Lin, I-Chia Liang, Kwan-Rong Liu |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
Vascular Endothelial Growth Factor A Intraocular pressure medicine.medical_specialty Triamcinolone acetonide Visual acuity genetic structures Visual Acuity Angiogenesis Inhibitors Triamcinolone Acetonide 03 medical and health sciences 0302 clinical medicine Edema Ophthalmology medicine Humans Pharmacology (medical) Adverse effect Aged Retrospective Studies Cerebrovascular Ischemia Aged 80 and over Pharmacology business.industry Middle Aged Acetonide Verteporfin Choroidal Neovascularization eye diseases Surgery Intravitreal Injections 030221 ophthalmology & optometry sense organs medicine.symptom business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Journal of Ocular Pharmacology and Therapeutics. 33:42-49 |
| ISSN: | 1557-7732 1080-7683 |
| DOI: | 10.1089/jop.2015.0150 |
| Popis: | To evaluate the efficacy and adverse effects of using low-dose intravitreal triamcinolone acetonide (IVTA) to preserve vision in polypoidal choroidal vasculopathy (PCV) eyes.This retrospective chart review study examined 8 eyes of 7 PCV patients, for whom verteporfin photodynamic therapy (vPDT) or antivascular endothelial growth factor (VEGF) therapy was not affordable/available and also with intolerable risk because of underlying cardiovascular and/or cerebrovascular ischemia. Low-dose IVTA (1 mg/0.025 mL) monotherapy was administered and repeated every 4 weeks if intraretinal edema or subretinal fluid persisted.The median follow-up time was 26.4 months. Three eyes (3/8) maintained their initial best-corrected visual acuity and 4 eyes (4/8) exhibited improvement, whereas 1 eye (1/8) sustained some loss. The mean injection number per month was 0.7 for the first 6 months, after which it decreased to 0.4. In regard to adverse effects, intraocular pressure (IOP) of more than 21 mmHg was noted as persisting for a few weeks in 4 eyes and that of more than 30 mmHg was noted once in 1 eye. The increased IOP was adequately controlled by using IOP-lowering agents. Two initially phakic eyes each underwent cataract surgery in the 12th and 14th months after treatment.Low-dose IVTA therapy may be valuable for preserving the vision of PCV patients, while vPDT or anti-VEGF is not affordable/available or of those with underlying diseases for whom anti-VEGF therapy is with intolerable risk. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|